



# WHO Advisory Committee on Variola Virus Research

Report of the Fifteenth Meeting

Geneva, Switzerland

24–25 September 2013





WHO/HSE/PED/CED/2013.2

# **WHO Advisory Committee on Variola Virus Research**

Report of the Fifteenth Meeting

Geneva, Switzerland

24–25 September 2013

© World Health Organization 2013

All rights reserved.

Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO web site ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

## **Table of Contents**

Executive Summary .....	3
1. Report of the Secretariat .....	5
2. Update on WHO-approved research proposals.....	5
3. Update on variola virus stocks held in the repositories in the United States and the Russian Federation .....	5
4. Update on laboratory diagnostic tests.....	6
5. Update on animal models .....	7
6. Update on vaccines.....	7
7. Update on antiviral agents and therapeutics .....	8
8. Regulatory issues.....	10
9. Smallpox diagnostic network.....	11
10. WHO smallpox vaccines stocks.....	11
11. Update on variola virus repositories biosafety inspections .....	12
12. General discussion.....	12
Annex 1: Summary of presentations .....	16
Annex 2: Agenda .....	39
Annex 3: List of participants .....	42

*WHO Advisory Committee on Variola Virus Research*  
*Report of the Fifteenth Meeting, Geneva, Switzerland, 24–25 September 2013*

## **Executive Summary**

On 24 and 25 September 2013 the Advisory Committee on Variola Virus Research held its fifteenth meeting. In addition to its regular annual review of the virus stocks held in the two authorized repositories, the research undertaken and the proposals submitted, the Advisory Committee took the opportunity to review all research conducted over the past three years. The intention behind this in-depth review was to contribute to preparations for the forthcoming discussion at the Sixty-seventh World Health Assembly in May 2014 on the timing of the destruction of variola virus stocks.

The Advisory Committee was provided with reports on the virus collections held at the two WHO Collaborating Centres that are authorized as repositories of variola virus: the State Research Centre for Virology and Biotechnology, Koltsovo, Novosibirsk Region, Russian Federation and the Centers for Disease Control and Prevention (CDC) Atlanta, Georgia, United States of America.

The Advisory Committee was also provided with updates on the use of live variola virus for the development of: diagnostic tests, one animal model, smallpox vaccines, and antiviral agents and therapeutics. Representatives of two pharmaceutical companies described candidate antiviral agents (tecovirimat and brincidofovir) that were in an advanced stage of development. Information presented included data on efficacy, safety, stability and large-scale manufacturing capacity. Work is continuing to provide the data that are needed to satisfy the requirements for regulatory approval. A representative of another pharmaceutical company provided an update on its vaccine that had been licensed in the 28 Member States of the European Union, plus Iceland, Liechtenstein and Norway, in August 2013, with the indication for active immunization against smallpox of all adults.

Members of the Committee were asked to consider whether live variola virus was needed for further essential research for public health benefit on diagnostics for smallpox. The majority view within the committee was that there was no need to retain live variola virus for development of further diagnostics for smallpox.

Members of the Committee were asked to consider whether live variola virus was needed for further essential research for public health benefit on vaccines against smallpox. The majority view within the committee was that there was no need to retain live variola virus for the development of safer smallpox vaccines beyond those studies already approved.

Members of the Committee were asked to consider whether live variola virus was needed for further essential research for public health benefit on antivirals for smallpox. The majority view within the committee was that live variola virus was needed for the further development of antiviral agents against smallpox.

The CDC's "use to completion" of 70 of its 420 variola virus stocks in the process of approved research has set a potential precedent for the progressive reduction of all live virus material being held in the two repositories as a means of meeting the request of the World Health Assembly.

The Advisory Committee was appraised of other consultations, the outcome of which would have relevance to discussions to be held at the Sixty-seventh WHA. These consultations were as follows:

- The Advisory Group of Independent Experts to review the smallpox research programme (AGIES) would be reconvened in November 2013 to consider the recommendations and decisions of the Advisory Committee.
- An expert consultation aimed at reviewing the evidence on smallpox vaccines and proposing recommendations for the size and composition of the WHO smallpox vaccine stockpile had been convened on 19 and 20 September 2013. That consultation will present its conclusions and recommendations to the Strategic Advisory Group of Experts (SAGE) on Immunization for consideration at meeting in November 2013.

In further preparation for the discussions at the World Health Assembly in May 2014, the reports of 15<sup>th</sup> meeting of ACCVR, AGIES and SAGE, as well as that of the Secretariat, would be submitted to the Executive Board of WHO for consideration at its 134th session in January 2014.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28029](https://www.yunbaogao.cn/report/index/report?reportId=5_28029)

